Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing

Core Viewpoint - Myriad Genetics expresses strong disagreement with UnitedHealthcare's updated medical policy that restricts access to its GeneSight test, citing insufficient evidence of efficacy as the rationale for the change [2][3] Company Summary - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health and well-being through genetic insights [6] - The GeneSight test is a pharmacogenomic test for over 60 medications commonly prescribed for mental health conditions, with nearly 3 million tests conducted to date [3][5] - The company believes in the clinical validity and utility of GeneSight, supported by peer-reviewed research, especially in the context of the ongoing mental health crisis [3] Industry Context - The updated policy from UnitedHealthcare will take effect on January 1, 2025, impacting access to multi-gene panel pharmacogenetic tests under its commercial and individual exchange benefit plans [1] - Myriad Genetics is actively engaging with UnitedHealthcare to discuss the evidence supporting GeneSight and to ensure continued access for enrollees [2] - The company remains optimistic about favorable coverage determinations from other health plans and does not believe the updated policy will affect GeneSight coverage under Medicare Advantage and managed Medicaid plans [3]